Bioventix Plc Director/PDMR Shareholding

 
TIDMBVXP 
 
Bioventix plc 
                        ("Bioventix" or the "Company") 
 
                          Director/PDMR Shareholding 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, announces that it has been notified that Peter Harrison, 
Chief Executive, has dealt in the Ordinary Shares of 5 pence each (the 
"Ordinary Shares") as follows: 
 
  * On 1 April 2020, the sale of 30,000 Ordinary Shares at 3,600 pence per 
    Ordinary Share (the "Sale"); and 
 
  * On 2 April 2020, the exercise of options over 18,500 Ordinary Shares at 
    1,350 pence per Ordinary Share (the "Option Shares"), pursuant to the 
    Company's 2013 EMI Share Option Scheme (the "Exercise") (details of which 
    can be found at www.bioventix.com). 
 
Following the Sale and the Exercise, Peter Harrison's total beneficial interest 
in the Company will be 416,676 Ordinary Shares representing approximately 8.0% 
of the Company. 
 
Following the Exercise, the Company has applied for 18,500 Ordinary Shares to 
be admitted to trading on AIM ("Admission"). It is expected that Admission will 
occur and that dealings will commence in the Option Shares on 8 April 2020. The 
Option Shares will rank pari passu with the existing Ordinary Shares. 
 
The total number of Ordinary Shares in issue following Admission will be 
5,207,835 and the Company holds no shares in treasury. Therefore, the total 
number of Ordinary Shares with voting rights in the Company will be 5,207,835. 
 
The above figure of 5,207,835 may be used by shareholders as the denominator 
for the calculations by which they will determine if they are required to 
notify their interest in, or a change to their interest in, Bioventix under the 
FCA's Disclosure Guidance and Transparency Rules. 
 
For further information please contact: 
 
Bioventix plc                                         Tel: 01252 728 001 
Peter Harrison             Chief Executive Officer 
 
finnCap Ltd                                           Tel: 020 7220 0500 
Geoff Nash/Simon Hicks     Corporate Finance 
Alice Lane                 ECM 
 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
1        Details of the person discharging managerial responsibilities ("PDMR") / 
         person closely associated ("PCA") 
 
a)       Name                      Peter Harrison 
 
2.       Reason for the Notification 
 
a)       Position/status           Chief Executive Officer 
 
b)       Initial notification/     Initial notification 
         Amendment 
 
3.       Details of the issuer, emission allowance market participant, auction 
         platform, auctioneer or auction monitor 
 
a)       Name                      Bioventix plc 
 
b)       LEI                       213800225MHX7LZQY108 
 
4.       Details of the transaction(s): section to be repeated for (i) each type of 
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each 
         place where transactions have been conducted 
 
a)       Description of the        Ordinary Shares of 5 pence each 
         Financial instrument, 
         type of instrument 
 
         Identification code       GB00B4QVDF07 
 
b)       Nature of the transaction Sale of Ordinary Shares 
 
c)       Price(s) and volume(s)    Price(s)              Volume(s) 
 
                                   3,600p                30,000 
 
d)       Aggregated information: 
         ·     Aggregated volume   30,000 
 
         ·     Price               3,600p 
 
e)       Date of the transaction   1 April 2020 
 
f)       Place of the transaction  London Stock Exchange, AIM Market (XLON) 
 
 
 
1        Details of the person discharging managerial responsibilities ("PDMR") / 
         person closely associated ("PCA") 
 
a)       Name                      Peter Harrison 
 
2.       Reason for the Notification 
 
a)       Position/status           Chief Executive Officer 
 
b)       Initial notification/     Initial notification 
         Amendment 
 
3.       Details of the issuer, emission allowance market participant, auction 
         platform, auctioneer or auction monitor 
 
a)       Name                      Bioventix plc 
 
b)       LEI                       213800225MHX7LZQY108 
 
4.       Details of the transaction(s): section to be repeated for (i) each type of 
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each 
         place where transactions have been conducted 
 
a)       Description of the        Options over Ordinary Shares of 5 pence each 
         Financial instrument, 
         type of instrument 
 
         Identification code       GB00B4QVDF07 
 
b)       Nature of the transaction Exercise of Options 
 
c)       Price(s) and volume(s)    Price(s)              Volume(s) 
 
                                   1,350p                18,500 
 
d)       Aggregated information: 
         ·     Aggregated volume   18,500 
 
         ·     Price               1,350p 
 
e)       Date of the transaction   2 April 2020 
 
f)       Place of the transaction  London Stock Exchange, AIM Market (XLON) 
 
 
 
END
(END) Dow Jones Newswires
April 02, 2020 09:21 ET (13:21 GMT)
Bioventix (AQSE:BVXP.GB)
Historical Stock Chart
From Dec 2024 to Jan 2025